Back to News
Market Impact: 0.3

Validea Detailed Fundamental Analysis

AMGNNDAQ
Healthcare & BiotechCompany FundamentalsAnalyst InsightsInvestor Sentiment & PositioningCapital Returns (Dividends / Buybacks)
Validea Detailed Fundamental Analysis

Validea's guru fundamental report assigns AMGEN (AMGN) an 87% rating using the Pim van Vliet Multi-Factor Investor model, which prioritizes low volatility stocks with strong momentum and high net payout yields. This score, indicating significant interest for a large-cap growth biotechnology stock, suggests AMGN aligns well with a strategy focused on outperforming with reduced risk.

Analysis

Amgen, Inc. (AMGN) has been assigned a high rating of 87% by Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy of targeting low-volatility stocks with strong momentum and high net payout yields. As a large-cap biotechnology stock, AMGN passed the model's criteria for market capitalization and standard deviation, confirming its low-volatility characteristic, which is the cornerstone of this investment paradox strategy. However, the analysis reveals a significant nuance: despite the high score, the stock received a 'NEUTRAL' rating on both its 'Twelve Minus One Momentum' and 'Net Payout Yield'. This weakness culminates in a 'FAIL' on the model's 'FINAL RANK'. This discrepancy suggests that while AMGN exhibits the desirable defensive trait of low volatility, it currently lacks the strong momentum and shareholder return profile required to fully satisfy the quantitative screen, presenting a mixed signal for factor-based investors.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment